Abbott Laboratories (ABT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
Cash Flows From Operating Activities | |||||
Net Income | 2,368,000 | 477,000 | 1,400,000 | 4,423,000 | 2,284,000 |
Depreciation Amortization | 3,310,000 | 3,933,000 | 1,518,000 | 1,472,000 | 1,548,000 |
Accounts receivable | -190,000 | -207,000 | -177,000 | -171,000 | -195,000 |
Other Working Capital | -148,000 | 1,915,000 | -1,513,000 | -156,000 | -490,000 |
Other Operating Activity | 960,000 | -548,000 | 1,975,000 | -2,602,000 | 528,000 |
Operating Cash Flow | $6,300,000 | $5,570,000 | $3,203,000 | $2,966,000 | $3,675,000 |
Cash Flows From Investing Activities | |||||
PPE Investments | -1,394,000 | -1,135,000 | -1,121,000 | -1,110,000 | -1,077,000 |
Net Acquisitions | -6,000 | -11,141,000 | -55,000 | 2,285,000 | -3,312,000 |
Purchase Of Investment | -131,000 | -210,000 | -2,823,000 | -4,933,000 | -1,507,000 |
Sale Of Investment | 73,000 | 129,000 | 3,709,000 | 4,112,000 | 5,624,000 |
Other Investing Activity | 102,000 | 2,739,000 | 42,000 | 52,000 | 70,000 |
Investing Cash Flow | $-1,356,000 | $-9,618,000 | $-248,000 | $406,000 | $-202,000 |
Cash Flows From Financing Activities | |||||
Change In Short Term Borrowing | -26,000 | -1,034,000 | -1,767,000 | -1,281,000 | 1,343,000 |
Debt Issued | 4,009,000 | 6,742,000 | 14,934,000 | 2,485,000 | 0 |
Debt Repayment | -12,433,000 | -8,650,000 | -12,000 | -57,000 | -577,000 |
Common Stock Issued | 271,000 | 350,000 | 248,000 | 314,000 | 429,000 |
Common Stock Repurchased | -238,000 | -117,000 | -522,000 | -2,237,000 | -2,195,000 |
Dividend Paid | -1,974,000 | -1,849,000 | -1,539,000 | -1,443,000 | -1,342,000 |
Other Financing Activity | 0 | -723,000 | -195,000 | -17,000 | -400,000 |
Financing Cash Flow | $-10,391,000 | $-5,281,000 | $11,147,000 | $-2,236,000 | $-2,742,000 |
Exchange Rate Effect | -116,000 | 116,000 | -483,000 | -198,000 | -143,000 |
Beginning Cash Position | 9,407,000 | 18,620,000 | 5,001,000 | 4,063,000 | 3,475,000 |
End Cash Position | 3,844,000 | 9,407,000 | 18,620,000 | 5,001,000 | 4,063,000 |
Net Cash Flow | $-5,563,000 | $-9,213,000 | $13,619,000 | $938,000 | $588,000 |
Free Cash Flow | |||||
Operating Cash Flow | 6,300,000 | 5,570,000 | 3,203,000 | 2,966,000 | 3,675,000 |
Capital Expenditure | -1,394,000 | -1,135,000 | -1,121,000 | -1,110,000 | -1,077,000 |
Free Cash Flow | 4,906,000 | 4,435,000 | 2,082,000 | 1,856,000 | 2,598,000 |